ASCO成人癌症幸存者化疗所致周围神经病变预防与管理指南更新
该更新基于针对性系统文献综述,纳入3篇系统综述(其中2篇含荟萃分析)及28项预防性primary试验和14项治疗性primary试验。推荐 reconfirm 无药物可用于预防CIPN,不鼓励使用乙酰左旋肉碱预防,度洛西汀是唯一有适当证据支持用于已确立的疼痛性CIPN的药物但获益有限。
要点
- 不推荐任何药物用于预防化疗所致周围神经病变(CIPN)。
- 应劝阻使用乙酰左旋肉碱预防CIPN。
- 度洛西汀是唯一有证据支持用于已确立疼痛性CIPN的药物,但获益有限。
核心结论
- reconfirm 无药物推荐用于预防CIPN,且应劝阻使用乙酰左旋肉碱预防CIPN。
- 度洛西汀是唯一有适当证据支持用于已确立疼痛性CIPN的药物,但获益有限。
研究设计与样本
- Expert Panel conducted targeted systematic literature reviews to identify new studies.
- Search identified 257 new references leading to full-text review of 87 manuscripts.
- Included 3 systematic reviews (2 with meta-analyses), 28 primary prevention trials, and 14 primary treatment trials for established CIPN.
主要发现
- Identified data reconfirmed that no agents are recommended for prevention of CIPN.
- Use of acetyl-l-carnitine for prevention of CIPN should be discouraged.
- Duloxetine is the only agent with appropriate evidence for established painful CIPN, though benefit is limited.
关键数值与推荐
- No agents recommended for CIPN prevention.
- Acetyl-l-carnitine should be discouraged for CIPN prevention.
- Duloxetine recommended for established painful CIPN with limited benefit.
临床怎么用
- Clinicians should assess appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment.
- For patients with established painful CIPN, duloxetine may be used with awareness of limited benefit.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS: An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS: The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS: The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.Additional information is available at www.asco.org/survivorship-guidelines.
引用
- Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020. PMID: 32663120. doi:10.1200/JCO.20.01399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。